12:00 AM
 | 
Sep 24, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Aerospan flunisolide HFA regulatory update

FDA approved an sNDA from Acton for Aerospan flunisolide HFA as maintenance treatment of asthma in patients >=6 years of age. Acton plans to launch the hydrofluoroalkane (HFA)-propelled inhaled formulation of flunisolide in the U.S. early next year.

Read the full 174 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >